Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar, Anita J. , Hemmer, Michael, Arora, Mukta , Pidala, Joseph A. , Couriel, Daniel R. , Aljurf, Mahmoud , Cahn, Jean‐Yves, Cairo, Mitchell S. , Farhan, Shatha , Hale, Gregory A., Hashmi, Shahrukh K. , Inamoto, Yoshihiro , Kamble, Rammurti T., Kharfan‐Dabaja, Mohamed A. , MacMillan, Margaret L. , Marks, David I. , Norkin, Maxim , Ringdén, Olle , Schouten, Harry C. , Solh, Melhem , Urbano-Ispizúa, Álvaro , Verdonck, Leo F. , Hamilton, Betty K. , Majhail, Navneet S. , Loren, Alison W. , Ringden, Olov , Majhail, Navneet S , Kim, Soyoung , Spellman, Stephen R. , Alousi, Amin Majid , Cahn, Jean‐Yves , Cutler, Corey S. , Gergis, Usama , Nakasone, Hideki , Qayed, Muna , Schultz, Kirk R. , Teshima, Takanori , Gale, Robert Peter

Mayo Clinic

Blood Advances | May 8, 2018 | Volume: 2 | Issue: 9 | Pages: 1022-1031

10.1182/bloodadvances.2017013052 | PMID 29739773 Get It

Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
Association Between Adiposity and Lean Mass With Long‐Term Cardiovascular Events in Patients With Coronary Artery Disease: No Paradox
Medina‐Inojosa, José R. , Jean, Nathalie, Jenkins, Sarah M. , Gomez‐Ibarra, Miguel Angel, Supervía, Marta , Gomez-Ibarra, Miguel Angel, Medina-Inojosa, José R , Somers, Virend K. , Thomas, Randal J. , López-Jiménez, Francisco

Mayo Clinic

Journal of the American Heart Association | May 8, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1161/jaha.117.007505 | PMID 29739793 Get It

Background Prognosis based on body fat percentage ( BF %) in patients with coronary artery disease has not been extensively studied. We tested the hypothesis that patients with coronary artery disease and increased BF % have a higher risk for major adverse cardiovascular events ( MACEs ) and that fat‐free mass is associated with better prognosis. Methods and Results We included 717 patients referred to cardiac rehabilitation after coronary artery disease events or procedures who underwent air displacement plethysmography to assess BF %; 75% were men, with a mean age 61.4±11.4 years and a mean body mass index of 30±5.4 kg/m 2 . Follow‐up was performed using a record linkage system. Patients were classified in sex‐specific quartiles of BF % and fat‐free mass index. The composite outcome of MACEs included acute coronary syndromes, coronary revascularization, stroke, or death from any cause. After a median follow‐up of 3.9 years, 201 patients had a MACE . After adjusting for covariates, body mass index was not associated with MACEs ( P =0.12). However, the risk of MACEs for those in the highest BF % quartile was nearly double when compared with those in the lowest quartile (hazard ratio, 1.89; 95% confidence interval, 1.30–2.77; P =0.0008). In contrast, fat‐free mass was inversely associated with MACEs . The risk of MACEs for those in the fourth fat‐free mass quartile was lower (adjusted hazard ratio, 0.53; 95% confidence interval, 0.35–0.82; P =0.004), when compared with those in the first quartile. Conclusions In patients with coronary artery disease, there is no obesity paradox when measuring BF % instead of body mass index. BF % is associated with a higher risk of MACEs , whereas fat‐free mass is associated with a lower risk of MACEs . Body mass index was not associated with MACEs .
Copy number variant analysis using genome‐wide mate‐pair sequencing
Smadbeck, James B. , Johnson, Sarah H. , Smoley, Stephanie A., Gaitatzes, Athanasios , Drucker, Travis, Zenka, Roman M. , Kosari, Farhad , Hoppman, Nicole L., Sukov, William R. , Jenkins, Robert B. , Kearney, Hutton M. , Vasmatzis, George , Drucker, Travis M, Hoppman, Nicole, Aypar, Umut , Murphy, Stephen J. , Feldman, Andrew L.

Mayo Clinic

Genes, Chromosomes and Cancer | May 4, 2018 | Volume: 57 | Issue: 9 | Pages: 459-470

10.1002/gcc.5 | PMID 29726617 Get It

AbstractCopy number variation (CNV) is a common form of structural variation detected in human genomes, occurring as both constitutional and somatic events. Cytogenetic techniques like chromosomal microarray (CMA) are widely used in analyzing CNVs. However, CMA techniques cannot resolve the full nature of these structural variations (i.e. the orientation and location of associated breakpoint junctions) and must be combined with other cytogenetic techniques, such as karyotyping or FISH, to do so. This makes the development of a next‐generation sequencing (NGS) approach capable of resolving both CNVs and breakpoint junctions desirable. Mate‐pair sequencing (MPseq) is a NGS technology designed to find large structural rearrangements across the entire genome. Here we present an algorithm capable of performing copy number analysis from mate‐pair sequencing data. The algorithm uses a step‐wise procedure involving normalization, segmentation, and classification of the sequencing data. The segmentation technique combines both read depth and discordant mate‐pair reads to increase the sensitivity and resolution of CNV calls. The method is particularly suited to MPseq, which is designed to detect breakpoint junctions at high resolution. This allows for the classification step to accurately calculate copy number levels at the relatively low read depth of MPseq. Here we compare results for a series of hematological cancer samples that were tested with CMA and MPseq. We demonstrate comparable sensitivity to the state‐of‐the‐art CMA technology, with the benefit of improved breakpoint resolution. The algorithm provides a powerful analytical tool for the analysis of MPseq results in cancer.
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al
Molenaar, Remco J. , Sidana, Surbhi , Kalaycio, Matt, Nazha, Aziz , Adelstein, David J. , Nasr, Christian , Maciejewski, Jaroslaw P. , Majhail, Navneet S. , Sekeres, Mikkael A. , Radivoyevitch, Tomas, Majhail, Navneed S, Mukherjee, Sudipto, Majhail, Navneet S , Sidana, Surbhi , Sekeres, Mikkael A , Radivoyevitch, Tomas , Gerds, Aaron T. , Carraway, Hetty E. , Mukherjee, Sudipto

Mayo Clinic

Journal of Clinical Oncology | May 3, 2018 | Volume: 36 | Issue: 18 | Pages: 1889-1892

10.1200/jco.2018.78.4074 | PMID 29723096 Get It

Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
Wei, Wei‐Qi, Li, Xiaohui , Feng, QiPing , Kubo, Michiaki , Peissig, Peggy , Karlson, Elizabeth W. , Jarvik, Gail P. , Shang, Ning , Larson, Eric , Shaffer, Christian M., Maeda, Shiro , Horikoshi, Momoko , Ritchie, Marylyn D. , Larson, Eric B. , Crosslin, David R. , Bland, Harris T. , Pacheco, Jennifer A. , Rasmussen‐Torvik, Laura J. , Cox, Nancy J. , Wilke, Russell A. , Rotter, Jerome I. , Momozawa, Yukihide , Roden, Dan M. , Krauss, Ronald M. , Denny, Joshua C. , Denny, Joshua C , Bland, Sarah T , Jarvik, Gail P , Wei, Wei-Qi , Rotter, Jerome I , Pacheco, Jennifer A , Kullo, Iftikhar J. , Lee, Ming Ta Michael , Edwards, Todd L. , Mosley, Jonathan D , Williams, Marc S , Cronkite, David , Hripcsak, George , Stein, Christoph , Roden, Dan M. , Feng, Qiping , Rasmussen-Torvik, Laura J

Mayo Clinic

Circulation | April 27, 2018 | Volume: 138 | Issue: 17 | Pages: 1839-1849

10.1161/circulationaha.117.031356 | PMID 29703846 Get It

Background: Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. Methods: We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then sought replication of candidate variants in another 160 cases and 1112 controls from a fifth Electronic Medical Records and Genomics site, which joined the network after the initial genome-wide association study. Finally, we performed a phenome-wide association study for other traits linked to the most significant locus. Results: The meta-analysis identified 7 single nucleotide polymorphisms at a genome-wide level of significance within the LPA/PLG locus associated with CHD events on statin treatment. The most significant association was for an intronic single nucleotide polymorphism within LPA/PLG (rs10455872; minor allele frequency, 0.069; odds ratio, 1.58; 95% confidence interval, 1.35–1.86; P =2.6×10 − 10 ). In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14–2.57; P =0.009). The association of this single nucleotide polymorphism with CHD events was independent of statin-induced change in low-density lipoprotein cholesterol (odds ratio, 1.62; 95% confidence interval, 1.17–2.24; P =0.004) and persisted in individuals with low-density lipoprotein cholesterol ≤70 mg/dL (odds ratio, 2.43; 95% confidence interval, 1.18–4.75; P =0.015). A phenome-wide association study supported the effect of this region on coronary heart disease and did not identify noncardiovascular phenotypes. Conclusions: Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.
0867 Sleep Duration and Hypertension among >700,000 Adults by Age and Sex: A Report of the National Healthy Sleep Awareness Project
Grandner, Michael A. , Mullington, Janet , Hashmi, Sarah D., Redeker, Nancy S. , Watson, Nathaniel F. , Morgenthaler, Timothy I.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A322-A322

10.1093/sleep/zsy061.866 Get It

Influence of the Vibralung Acoustical Percussor on pulmonary function and sputum expectoration in individuals with cystic fibrosis
Wheatley, Courtney M. , Baker, Sarah E. , Daines, C, Phan, Hanna , Martínez, Marina González, Snyder, Eric M., Wheatley-Guy, Courtney M , Morgan, Wayne J. , Baker, Sarah E

Mayo Clinic

Therapeutic Advances in Respiratory Disease | April 26, 2018 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1753466618770997 | PMID 29697011 Get It

Background: The Vibralung Acoustical Percussor is a new airway clearance therapy (ACT) utilizing intrapulmonary sound waves in addition to positive expiratory pressure (PEP). We evaluated the safety of the Vibralung and collected preliminary data on its ability to mediate sputum expectoration in individuals with cystic fibrosis (CF). Methods: Over two separate studies, 10 and 11 mild to moderate CF patients were recruited for study I and II, respectively. Study I: Vibralung was used for 20 min with either no sound (NS: PEP only) or sound (S: PEP and sound) on randomized visits. Pulmonary function, diffusion capacity of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO), symptoms, and peripheral oxygen saturation (SpO2) were measured at baseline and at 1 and 4 h post treatment. Expectorated sputum was collected over 4 h post treatment. Study II: over 5 days of in-hospital therapy, the Vibralung or vibratory vest therapy (Vest) were used for two therapy sessions per day, with sputum collected for 20 min following each therapy and pulmonary function accessed pre and post each 5-day period (days 1–5 or 7–11) in a randomized crossover design. Results: Vibralung usage resulted in no change from baseline to 4 h post in pulmonary function, SpO2 or symptoms ( p > 0.05). At 4 h post therapy, the DLCO- and DLNO-derived measure of alveolar–capillary unit function (DM/ VC) showed improvement (DM/ VC = 12.5 ± 5.5 versus 7.3 ± 18.8% change, S versus NS) with no difference between S and NS ( p = 0.74). Sputum expectoration was similar between S and NS conditions (wet sputum = 10.5 ± 4.6 versus 9.9 ± 3.2 g, S versus NS, p = 0.25). There were no differences in the improvement in pulmonary function between Vibralung and Vest during either 5-day period during the hospital stay. Conclusions: Vibralung was well tolerated and caused no detrimental changes in pulmonary function metrics. The Vibralung appears to be a safe ACT in individuals with CF.
A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials
Boers, Maarten , Singh, Jasvinder A. , Cofield, Stacey S. , Bridges, S. Louis , Moreland, Larry W. , O’Dell, James R., Wu, Hongsheng, Curtis, Jeffrey R. , Curtis, Jeffrey R , Singh, Jasvinder A , Moreland, Larry W , Leatherman, Sarah M.

Mayo Clinic

Arthritis Care & Research | April 25, 2018 | Volume: 71 | Issue: 2 | Pages: 319-322

10.1002/acr.23590 | PMID 29691998 Get It

ObjectiveThe Outcome Measures in Rheumatology (OMERACT) 3×3 method analyzes the occurrence of benefit and harm simultaneously at the individual patient level. We applied this method to 2 recent rheumatoid arthritis (RA) trial data sets.MethodsThe Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) and the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as having no adverse events (AEs), non‐serious AEs, and serious AEs. Treatment efficacy was defined as good, moderate, or no response. A good treatment response without any AEs was labeled an unqualified success, and no treatment response but at least 1 AE was considered an unmitigated failure. The association between benefit and harm was assessed by chi‐square or exact tests, as appropriate.ResultsIn TEAR, 612 of 755 patients had response data at 48 weeks: 14% of patients experienced unqualified success and 9% had unmitigated failure, with no difference between the treatment arms. Treatment response and AE rates were not correlated. In RACAT, 309 of 353 patients had response data at 48 weeks: 6% of patients experienced unqualified success and 11% had unmitigated failure, with no differences between the treatment arms. Response and AE rates were negatively correlated. The frequency of AEs and serious AEs increased as response decreased (P = 0.008).ConclusionWe found some evidence that clinical response may be reduced by the co‐occurrence of AEs.
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fathi, Amir T. , Fenaux, Pierre , Litzow, Mark R. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich, Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Germing, Ulrich , Serrano, Josefina , Zeidan, Amer M

Mayo Clinic

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932

10.1182/bloodadvances.2018016121 | PMID 29685952 Get It

Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.